This cross-sectional study highlights the significant impact of moderate-to-severe atopic dermatitis (AD) on quality of life and economic burden among adult patients in the Asia-Pacific region. The findings reveal substantial impairment in quality of life, with high levels of pain, discomfort, and anxiety reported, alongside considerable annual costs associated with the condition. The study emphasizes the need for proactive management of AD and its comorbidities to alleviate this burden.

This study compares the perspectives of patients with atopic dermatitis and dermatologists in the Asia-Pacific region regarding treatment goals and communication. While both groups largely agree on treatment objectives, patients prioritize prevention of exacerbations and minimizing side effects more than dermatologists, and a notable percentage of patients expressed dissatisfaction with communication despite overall satisfaction with treatment. The findings highlight areas for improvement in patient-centered care.

This study aims to develop highly accurate machine learning models using automated machine learning (AutoML) to predict necessary therapy changes and identify factors influencing disease progression in patients with psoriasis vulgaris and psoriatic arthritis. The results indicate that specific patient features, such as initial therapeutic agents and quality of life changes, significantly impact treatment decisions and disease outcomes, ultimately enhancing clinical decision-making for improved patient care.

The research emphasizes the benefits of a multidisciplinary approach in managing atopic dermatitis (AD), a chronic inflammatory skin disorder that significantly impacts patients’ quality of life. By accurately assessing individual risk profiles and enhancing patient-physician decision-making, this approach aims to improve treatment outcomes and overall care for patients with moderate-to-severe AD. The review calls for more data to establish standardized patient profiles and strategies for effective AD management.

Ustekinumab is an interleukin 12/23 inhibitor approved for moderate-to-severe plaque psoriasis and psoriatic arthropathy, and this review highlights its dermatological implications and applications. The findings indicate that ustekinumab is effective not only for psoriasis but also for various other dermatological conditions, including hidradenitis suppurativa and alopecia areata, and is particularly beneficial for childhood psoriasis and adult patients with concurrent Crohn’s disease.